Prostate cancer is the most common cancer with an estimated 2,707,821 men living with prostate cancer in the U.S. in 2011. It is estimated that 220,800 new cases prostate cancer will be diagnosed in 2015. Radiation therapy is a common treatment for prostate cancer with up to 42% of patients receiving this treatment (1). Prostate cancer has a high 5-year survival rate at 98.9%, however the estimated 27,450 deaths from prostate cancer represent about 10% of all cancer deaths in men. In addition, many prostate cancer survivors who have been treated with radiation therapy experience incontinence, erectile dysfunction, and bowel complications. In all, these complications can affect more than 50% of the prostate cancer patients treated with radiation. Hence, the quality of life for patients may greatly increase from a therapy to protect against these radiation side effects.
BIO 300’s ability to increase tumor growth delay has been investigated using both androgen-independent and androgen-dependent cell lines in a murine xenograft models of prostate cancer with or without radiation therapy. BIO 300 alone and in combination with radiation treatment, both significantly increases tumor growth delay compared to the respective controls. Importantly, BIO 300 had a therapeutic benefit on both androgen-independent and androgen-dependent tumor growth.
BIO 300 is also being evaluated to prevent the incidence of erectile dysfunction (ED) associated with radiation of the prostate. 35-50% of all prostate radiotherapy patients will develop ED.
Additional results pending publication.
- Siegel, R. et al. Cancer treatment and survivorship statistics, CA. Cancer J. Clin. 62, 220–41 (2012)